Private Wealth Partners LLC bought a new position in Boston Scientific Corp. (NYSE:BSX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $304,000.
Several other large investors also recently made changes to their positions in BSX. IFP Advisors Inc raised its position in Boston Scientific Corp. by 55.5% in the first quarter. IFP Advisors Inc now owns 6,242 shares of the company’s stock valued at $117,000 after buying an additional 2,228 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new position in Boston Scientific Corp. during the first quarter valued at $145,000. Rockefeller Financial Services Inc. acquired a new position in Boston Scientific Corp. during the second quarter valued at $256,000. Checchi Capital Advisers LLC raised its position in Boston Scientific Corp. by 3.4% in the second quarter. Checchi Capital Advisers LLC now owns 10,944 shares of the company’s stock valued at $256,000 after buying an additional 358 shares during the last quarter. Finally, FDO Partners LLC acquired a new position in Boston Scientific Corp. during the first quarter valued at $209,000. 92.06% of the stock is currently owned by institutional investors.
Boston Scientific Corp. (NYSE:BSX) traded down 0.94% during midday trading on Tuesday, reaching $23.28. The company had a trading volume of 5,918,442 shares. The stock’s 50 day moving average is $23.81 and its 200 day moving average is $22.50. Boston Scientific Corp. has a one year low of $15.67 and a one year high of $24.79. The company’s market capitalization is $31.68 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.27 EPS for the quarter, hitting analysts’ consensus estimates of $0.27. Boston Scientific Corp. had a positive return on equity of 22.66% and a negative net margin of 4.34%. The business earned $2.13 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter last year, the company posted $0.22 earnings per share. Boston Scientific Corp.’s quarterly revenue was up 15.4% on a year-over-year basis. Equities research analysts forecast that Boston Scientific Corp. will post ($0.02) earnings per share for the current fiscal year.
BSX has been the topic of several recent analyst reports. Leerink Swann reissued a “buy” rating and set a $27.50 price target (up from $25.50) on shares of Boston Scientific Corp. in a research report on Friday, June 17th. Argus upgraded Boston Scientific Corp. from a “hold” rating to a “buy” rating and boosted their target price for the company from $23.82 to $33.00 in a research note on Thursday, September 1st. They noted that the move was a valuation call. JPMorgan Chase & Co. boosted their target price on Boston Scientific Corp. from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, July 29th. Guggenheim initiated coverage on Boston Scientific Corp. in a research note on Wednesday, June 8th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Zacks Investment Research downgraded Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Five investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. Boston Scientific Corp. has a consensus rating of “Buy” and an average price target of $25.03.
In other news, EVP Timothy A. Pratt sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $24.46, for a total transaction of $587,040.00. Following the completion of the sale, the executive vice president now owns 287,495 shares in the company, valued at $7,032,127.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP John Bradley Sorenson sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $23.90, for a total value of $59,750.00. Following the sale, the senior vice president now owns 12,615 shares of the company’s stock, valued at approximately $301,498.50. The disclosure for this sale can be found here. Corporate insiders own 1.31% of the company’s stock.
Boston Scientific Corp. Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corp. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related companies with MarketBeat.com's FREE daily email newsletter.